LABT on Nasdaq

Lakewood-Amedex Biotherapeutics Inc.

American pharmaceutical preparations company, incorporated in Nevada1

In its 2026 prospectus (Form S-1) the company says: “We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others.”18 It is headquartered in University Park, Florida.1 Its shares trade on Nasdaq under the symbol LABT.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerLABT on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersUniversity Park, Florida1
  • Incorporated inNV2
  • Business address8031 Cooper Creek Blvd., Suite 103, University Park, Fl 342012
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Corporate structure

Lakewood-Amedex Biotherapeutics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Lakewood-Amedex Biotherapeutics Inc.

  • WFI Equity, LLC Filed SCHEDULE 13G on Lakewood-Amedex Biotherapeutics Inc., latest Aug 14, 2026
  • Lindesfarne LLC Filed SCHEDULE 13G on Lakewood-Amedex Biotherapeutics Inc., latest Aug 6, 2026
  • HPW Investments Holding Ltd. Filed SCHEDULE 13G on Lakewood-Amedex Biotherapeutics Inc., latest Jun 23, 2026
  • Lakewood-Amedex Biotherapeutics Inc. University Park, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Lakewood-Amedex Biotherapeutics Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kelvin Cooper2026–now

Chief financial officer

  1. Peter Ceccacci2026–now
Board members and other officers (4)

Timeline

  1. Sep 29, 20268-K Shareholder vote8
  2. Jul 15, 20268-K Regulation FD disclosure9
  3. Jun 17, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed10
  4. May 1, 2026New chief executive Kelvin Cooper becomes CEO3
  5. Apr 28, 20268-K Executive or director change11

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202612

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

44 filings to the SEC since October 2021: 2 quarterly reports, 4 major events, 6 insider forms, 3 large holders, 29 other. The latest 20:

  1. Sep 29, 20268-K CURRENT REPORT EDGAR
  2. Sep 24, 2026EFFECT EDGAR
  3. Sep 18, 2026S-1 REGISTRATION STATEMENT EDGAR
  4. Aug 24, 2026DRS EDGAR
  5. Aug 17, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  6. Aug 14, 202610-Q QUARTERLY REPORT EDGAR
  7. Aug 14, 2026SCHEDULE 13G EDGAR
  8. Aug 10, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  9. Aug 10, 2026DEF 14A PROXY STATEMENT EDGAR
  10. Aug 6, 2026SCHEDULE 13G EDGAR
  11. Jul 30, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  12. Jul 15, 20268-K CURRENT REPORT EDGAR
  13. Jun 23, 2026SCHEDULE 13G EDGAR
  14. Jun 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  15. Jun 22, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  16. Jun 17, 20268-K CURRENT REPORT EDGAR
  17. May 26, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  18. May 26, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
  19. May 22, 202610-Q QUARTERLY REPORT EDGAR
  20. May 14, 2026424B4 PROSPECTUS EDGAR

The 44 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Kelvin Cooper,$190.4K$563.4K16
2025Peter Ceccacci,$160.0K$533.0K16
2025Thomas Balzer,$177.9K$488.7K16
2025Peter B. Corr$48.0K$48.0K16
2024CEO$409.2K$706.0K16
2024CMO$409.2K$656.2K16
2024CFO$290.3K$441.3K16
2024Executive Chair$48.0K$48.0K16

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Marex Group Ltd48,167$151.2K0.0%New
UBS Group AG4,098$12.9K0.0%New
Tower Research Capital LLC (TRC)624$2.0K0.0%New
Osaic Holdings, Inc.138$4330.0%New
Hrt Financial LP44,782$1400.0%New
Blue Trust, Inc.11$350.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Lakewood-Amedex Biotherapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLakewood-Amedex Biotherapeutics Inc.1
  • CIK0002079272
  • Employer ID (EIN)20-52743041
  • Filer status<br>emerging growth company1
  • Incorporated inNevada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address8031 Cooper Creek Blvd., Suite 103, University Park, FL 342011
  • Phone94122525151
  • Shares outstanding2,369,688 as of Aug 3, 202617
  • On EDGAR sinceJul 31, 20251
  • Filings44 in all: 424B3 (6), 3 (5), S-1/A (5), 8-K (4), EFFECT (3), S-1 (3), SCHEDULE 13G (3), 10-Q (2)1
    All 19 form types

    424B4 (2), DRS (2), 4 (1), 8-A12B (1), CERT (1), CORRESP (1), DEF 14A (1), DEFA14A (1), DRS/A (1), PRE 14A (1), UPLOAD (1)

  • Latest filingsQuarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Aug 10, 2026
    Latest 8-K (8-K) Sep 29, 2026

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18